Denali Therapeutics Inc (NAS:DNLI)
$ 20.61 -0.71 (-3.33%) Market Cap: 2.97 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 57/100

Denali Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 07:00PM GMT
Release Date Price: $25.04 (-0.20%)
Mayank Mamtani
B. Riley Securities, Inc. - Analyst

Good afternoon. This is Mayank Mamtani, senior biotech analyst. Thank you for joining us for our next company presentation. I am pleased to have with me Denali's Chief Scientific Officer, Joe Lewcock.

Joe thank you for making the time from the busy schedule to join us today. Really appreciate it. I think we'll pass it on to you. You have a set of slides that you'd like to walk through, and then I can come back at the end with Q&A. Please take it away.

Joe Lewcock
Denali Therapeutics Inc. - Chief Scientific Officer

Yeah, sounds good. Thanks, Mayank, for the introduction and really appreciate you having us. And super excited today to take you -- take everyone through a quick overview of what's going at Denali Therapeutics. So just to start, some very quick disclaimers before we get going, and then let's just dive into the data.

So Denali was founded about seven years ago really with the unique focus on addressing neurodegenerative disease. And when we say neurodegenerative disease, we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot